Lyell Immunopharma, a clinical-stage T-cell reprogramming company, has released initial clinical and translational data from its Phase 1 trial of LYL797. This first-generation reprogrammed ROR1 CAR T-cell product candidate, enhanced with proprietary anti-exhaustion technology, shows promising results in patients with triple-negative breast cancer (TNBC). The trial demonstrates dose-dependent antitumor clinical activity, along with the ability of LYL797 CAR T cells to proliferate, infiltrate tumors, and effectively target cancer cells in patients with relapsed/refractory disease.
Clinical Trial Results
The initial dataset primarily includes patients with TNBC, showcasing encouraging outcomes. At the 150 x 10^6 CAR T cell dose level, patients treated with LYL797 experienced an response rate (ORR) of 40% and a clinical benefit rate (CBR) of 60%. Across all dose levels assessed thus far, a CBR of 38% has been observed. These outcomes signify the potential effectiveness of LYL797 CAR T-cell therapy in treating TNBC.
Safety Profile
Treatment-related adverse events in patients without lung metastases were generally mild, with Grade 1 and 2 cytokine release syndrome (CRS) and headache being the most common. Expected cytopenia resulting from lymphodepletion was also reported. Notably, there were no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) attributed to LYL797. However, patients with lung metastases experienced pneumonitis, prompting separate and more gradual dose escalation in this specific group. No dose-limiting toxicities have been reported in patients without lung involvement, offering further optimism for the viability and safety of the treatment.
Future Directions
As the Phase 1 trial progresses, Lyell Immunopharma is currently administering prophylactic steroids to all patients before treatment with LYL797. This proactive measure aims to address any potential adverse effects and ensure the well-being of participants. By continuing to assess the efficacy and safety of LYL797 in larger patient cohorts, Lyell Immunopharma hopes to pave the way for more targeted and efficient CAR-T therapies for solid tumors.
Conclusion:
The Phase 1 trial of LYL797, a ROR1-targeted CAR-T cell product candidate enhanced with anti-exhaustion technology, presents encouraging preliminary data for the treatment of TNBC. The observed dose-dependent antitumor clinical activity, favorable safety profile, and absence of severe adverse events highlight the potential impact of LYL797 in addressing the needs of patients with relapsed/refractory disease. These findings have significant implications for the future of CAR-T therapy and provide renewed hope in the battle against solid tumors.
Comments